More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers has developed an active substance that might in future represent a new treatment option. This substance, known as KMI169, targets an enzyme that plays an important role in the development of prostate cancer.